OrisDX provides a saliva-based molecular detection method to check oral cavity pre-malignancies and cancers.
OrisDX provides a saliva-based molecular detection method to check oral cavity pre-malignancies and cancers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 5, 2022 | Grant | $200K | 1 | George Shultz Innovation Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
George Shultz Innovation Fund | Yes | Grant |